Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 17/20 | 0.78 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.78 |
| ▸ | MAPK8 | P45983 | 12/20 | 0.78 |
| ▸ | MAPK9 | P45984 | 12/20 | 0.78 |
| ▸ | MAPK10 | P53779 | 12/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12979724 | 0.91 | MAPK1 (0.72) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL16404559 | 0.89 | MAPK1 (0.82) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12979214 | 0.89 | MAPK1 (0.72) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12979401 | 0.88 | MAPK1 (0.71) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4680272 | 0.88 | MAPK1 (1.00) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12979713 | 0.87 | MAPK1 (0.71) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12979744 | 0.87 | MAPK1 (0.82) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| Hydrochloric Acid SCHEMBL4680213 | 0.87 | MAPK1 (0.98) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12979839 | 0.87 | MAPK1 (0.72) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4683081 | 0.86 | MAPK1 (0.82) | MAPK1PIK3CAMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962854-B1 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | TERNA ZENTARIS GMBH (DE) | 2015-05-06 | — | — | EP | claimed |
| US-8193186-B2 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2012-06-05 | — | — | US | claimed |
| EP-1636228-B1 | NOVEL PYRIDOPYRAZINES AND USE THEREOF AS KINASE MODULATORS | AETERNA ZENTARIS GMBH (DE) | 2008-10-22 | — | — | EP | claimed |
| US-20080113991-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | ZENTARIS GMBH (DE) | 2008-05-15 | — | — | US | claimed |
| US-7323468-B2 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2008-01-29 | — | — | US | claimed |
| US-20070275972-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2007-11-29 | — | — | US | claimed |
| US-7276507-B2 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2007-10-02 | — | — | US | claimed |
| US-20050032803-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | ZENTARIS GMBH (DE) | 2005-02-10 | — | — | US | claimed |
| US-20040266777-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2004-12-30 | — | — | US | claimed |
| WO-2017180817-A1 | TREATMENT OF SEPTICEMIA AND ARDS WITH ERK INHIBITORS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-10-19 | — | — | WO | disclosed |
| EP-1962854-B1 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | TERNA ZENTARIS GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-8937068-B2 | Pyridopyrazine derivatives and their use | ZENTARIS GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937068-B2 | Pyridopyrazine derivatives and their use | ZENTARIS GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937068-B2 | Pyridopyrazine derivatives and their use | ZENTARIS GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-7276507-B2 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20050032803-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | ZENTARIS GMBH (DE) | 2005-02-10 | — | — | US | disclosed |
| US-20040266777-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275972-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | MKI67, MAP4K2, MAP3K5 | MAPK1 29/4885PIK3CA 207/4885MAPK8 134/4885 |
| US-20040266777-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | PDXK, MKI67, MAP4K2 | MAPK1 17/4885PIK3CA 209/4885MAPK8 194/4885 |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | PLPBP, PDXK, MAP4K2 | MAPK1 58/4885PIK3CA 866/4885MAPK8 116/4885 |
| US-20050032803-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | MKI67, MAP4K2, MAP3K5 | MAPK1 29/4885PIK3CA 207/4885MAPK8 134/4885 |
| US-20080113991-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | MKI67, MAP4K2, MAP3K5 | MAPK1 29/4885PIK3CA 207/4885MAPK8 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.